OPUS GENETICS INC(IRD),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

IRD OPUS GENETICS INC

Market Closed 09-04 16:00:00 EDT

4.67

+0.07

+1.52%

盘后4.74

+0.07+1.57%

19:33 EDT

High4.80	Low4.40	Vol2.24M
Open4.53	D1 Closing4.60	Amplitude8.70%
Mkt Cap388.52M	Tradable Cap304.53M	Total Shares83.20M
T/O10.39M	T/O Rate3.43%	Tradable Shares65.21M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"IRD","market":"US","secType":"STK","nameCN":"OPUS GENETICS INC","latestPrice":4.67,"timestamp":1788552000000,"preClose":4.6,"halted":0,"volume":2239733,"hourTrading":{"tag":"盘后","latestPrice":4.7432,"preClose":4.67,"latestTime":"19:33 EDT","volume":2755,"amount":12962.189,"timestamp":1788564800825,"change":0.0732,"changeRate":0.015675,"amplitude":0.015675},"delay":0,"changeRate":0.01521739130434789,"floatShares":65209799,"shares":83195823,"eps":-1.292468,"marketStatus":"Market Closed","change":0.07,"latestTime":"09-04 16:00:00 EDT","open":4.53,"high":4.8,"low":4.4,"amount":10387457.672543101,"amplitude":0.086957,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-1.292468,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1788854400000},"marketStatusCode":7,"adr":0,"listingDate":1100235600000,"exchange":"NASDAQ","adjPreClose":4.6,"preHourTrading":{"tag":"盘前","latestPrice":4.55,"preClose":4.6,"latestTime":"09:29 EDT","volume":2157,"amount":9945.782481,"timestamp":1788528551984,"change":-0.05,"changeRate":-0.01087,"amplitude":0.11087},"postHourTrading":{"tag":"盘后","latestPrice":4.7432,"preClose":4.67,"latestTime":"19:33 EDT","volume":2755,"amount":12962.189,"timestamp":1788564800825,"change":0.0732,"changeRate":0.015675,"amplitude":0.015675},"volumeRatio":0.9571161694489513,"impliedVol":2.5531,"impliedVolPercentile":0.8016},"requestUrl":"/m/hq/s/IRD","defaultTab":"news","newsList":[{"id":"2664815949","title":"Opus Genetics to Report Phase 1/2 Cohort 1 Topline Data for OPGx-BEST1 Gene Therapy Sept. 9 Webcast","url":"https://stock-news.laohu8.com/highlight/detail?id=2664815949","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664815949?lang=en_us&edition=fundamental","pubTime":"2026-09-02 19:01","pubTimestamp":1788346876,"startTime":"0","endTime":"0","summary":"Opus Genetics to report Phase 1/2 Cohort 1 topline data for OPGx-BEST1 gene therapy Sept. 9 webcastOpus Genetics set a Sept. 9, 2026 investor webcast to present topline Phase 1/2 Cohort 1 data for OPG","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260902:nNDL2m3155:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2095319765.USD","BK4585","IE00BGHQF748.EUR","BK4588","IE00B64PRP62.GBP","LU2210150020.SGD","SG9999014039.USD","IE00BKPKM429.USD","BCDF","LU0314104364.USD","IRD","IE00BN0W2T93.GBP","IE00BQXX3C00.GBP","IE00BQXX3D17.EUR","BK4139","IE00BQXX3F31.USD","BK4112","SG9999014021.USD","NDAQ","SG9999014005.SGD","IE00B3QW5Z07.USD","BK4007","IE00BN0W2W23.USD","IE00BN0W2V16.EUR","SG9999014013.SGD","LU2210149790.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660747820","title":"Longeveron Appoints Nirav Jhaveri as Chief Financial Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2660747820","media":"THOMSON REUTERS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660747820?lang=en_us&edition=fundamental","pubTime":"2026-08-20 04:05","pubTimestamp":1787169900,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260819:nTUA3CJNSM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","BK4139","BK1141","LGVN","03696","IRD","DERM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660647873","title":"Longeveron - Marie Washburn Steps Down as CFO, Returns to Corporate Controller Role","url":"https://stock-news.laohu8.com/highlight/detail?id=2660647873","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660647873?lang=en_us&edition=fundamental","pubTime":"2026-08-20 04:05","pubTimestamp":1787169900,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260819:nTUA3CJNSM:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","DERM","LGVN","BK1141","BK4139","03696","IRD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660782854","title":"Opus Genetics Grants Options for 310,000 Shares Under Inducement Plan","url":"https://stock-news.laohu8.com/highlight/detail?id=2660782854","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660782854?lang=en_us&edition=fundamental","pubTime":"2026-08-20 04:01","pubTimestamp":1787169679,"startTime":"0","endTime":"0","summary":"Opus Genetics grants options for 310,000 shares under inducement planOpus Genetics granted stock options covering 310,000 shares to three newly hired non-executive employees under its 2021 Inducement ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260819:nNDL5337Ym:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BQXX3C00.GBP","IE00BQXX3D17.EUR","IE00B64PRP62.GBP","BK4112","IE00BN0W2T93.GBP","LU2210150020.SGD","IE00B3QW5Z07.USD","SG9999014021.USD","LU2095319765.USD","IE00BN0W2V16.EUR","BK4139","SG9999014039.USD","NDAQ","BCDF","BK4585","IE00BGHQF748.EUR","IE00BQXX3F31.USD","IE00BKPKM429.USD","LU0314104364.USD","BK4588","IE00BN0W2W23.USD","BK4007","LU2210149790.SGD","SG9999014005.SGD","IRD","SG9999014013.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660478420","title":"Opus Genetics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)","url":"https://stock-news.laohu8.com/highlight/detail?id=2660478420","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660478420?lang=en_us&edition=fundamental","pubTime":"2026-08-20 04:01","pubTimestamp":1787169660,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260819:nTUA446LXV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","IRD","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658499775","title":"Opus Genetics Inc Reports Results for the Quarter Ended June 30 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2658499775","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658499775?lang=en_us&edition=fundamental","pubTime":"2026-08-11 19:59","pubTimestamp":1786449579,"startTime":"0","endTime":"0","summary":"Opus Genetics Inc reports results for the quarter ended June 30 - Earnings SummaryOpus Genetics IncIRD.OQreported a quarterly adjusted loss of 14 cents per share for the quarter ended June 30, lower t","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260811:nL8N448103:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","IRD","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657647547","title":"Opus Genetics (IRD) Receives a Buy from Piper Sandler","url":"https://stock-news.laohu8.com/highlight/detail?id=2657647547","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657647547?lang=en_us&edition=fundamental","pubTime":"2026-08-07 23:27","pubTimestamp":1786116468,"startTime":"0","endTime":"0","summary":"Piper Sandler analyst Biren Amin maintained a Buy rating on Opus Genetics today and set a price target of $11.00. According to TipRanks, Amin is a ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/opus-genetics-ird-receives-a-buy-from-piper-sandler-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/opus-genetics-ird-receives-a-buy-from-piper-sandler-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IRD","BK4139","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657496386","title":"Cantor Fitzgerald Sticks to Their Buy Rating for Opus Genetics (IRD)","url":"https://stock-news.laohu8.com/highlight/detail?id=2657496386","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657496386?lang=en_us&edition=fundamental","pubTime":"2026-08-07 21:17","pubTimestamp":1786108667,"startTime":"0","endTime":"0","summary":"In a report released yesterday, Steven Seedhouse from Cantor Fitzgerald maintained a Buy rating on Opus Genetics, with a price target of $15.00. Th...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/cantor-fitzgerald-sticks-to-their-buy-rating-for-opus-genetics-ird-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/cantor-fitzgerald-sticks-to-their-buy-rating-for-opus-genetics-ird-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IRD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657454976","title":"RBC Adjusts PT on Opus Genetics to $9 From $10, Maintains Outperform Speculative Risk Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2657454976","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657454976?lang=en_us&edition=fundamental","pubTime":"2026-08-07 20:35","pubTimestamp":1786106149,"startTime":"0","endTime":"0","summary":"Opus Genetics (IRD) has an average rating of buy and mean price target of $10.71, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from major banks ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4007","IRD","IRD.AU","BK4139","BK7129"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657104006","title":"Opus Genetics Inc Expected to Post a Loss of 16 Cents a Share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2657104006","media":"Reuters","labels":["preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657104006?lang=en_us&edition=fundamental","pubTime":"2026-08-07 19:15","pubTimestamp":1786101307,"startTime":"0","endTime":"0","summary":"Opus Genetics Inc <IRD.OQ> expected to post a loss of16cents a share - Earnings PreviewOpus Genetics IncIRD.OQIRD.Ois expected to  show a fall in quarterly revenue when it reports  results  for the pe","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260807:nL8N4440Z3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IRD","BK4139","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657661254","title":"Opus Genetics - May Offer and Sell up to $300 Mln of Securities - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2657661254","media":"THOMSON REUTERS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657661254?lang=en_us&edition=fundamental","pubTime":"2026-08-07 18:19","pubTimestamp":1786097974,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260807:nFWN4432GS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","IRD","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657652347","title":"Wall Street Analysts Are Bullish on Top Healthcare Picks","url":"https://stock-news.laohu8.com/highlight/detail?id=2657652347","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657652347?lang=en_us&edition=fundamental","pubTime":"2026-08-07 03:30","pubTimestamp":1786044629,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Roivant Sciences (ROIV), Opus Genetics (IRD) and Reg...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/wall-street-analysts-are-bullish-on-top-healthcare-picks-blurbs-news-283?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/wall-street-analysts-are-bullish-on-top-healthcare-picks-blurbs-news-283?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","BK4139","IRD","PTH","ROIV"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657263345","title":"Opus Genetics Q2 EPS $(0.14) Beats $(0.16) Estimate, Sales $755.000K Miss $2.470M Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2657263345","media":"Benzinga Earnings","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657263345?lang=en_us&edition=fundamental","pubTime":"2026-08-06 19:29","pubTimestamp":1786015797,"startTime":"0","endTime":"0","summary":"Opus Genetics (NASDAQ:IRD) reported quarterly losses of $(0.14) per share which beat the analyst consensus estimate of $(0.16) by 12.5 percent. This is a 16.67 percent decrease over losses of $(0.12) per share from the","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/08/60989017/opus-genetics-q2-eps-0-14-beats-0-16-estimate-sales-755-000k-miss-2-470m-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IRD","BK4139","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657258638","title":"Opus Genetics Q2 FY26 Net Loss Widens to $8.1 Million; Revenue Drops to $755,000","url":"https://stock-news.laohu8.com/highlight/detail?id=2657258638","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657258638?lang=en_us&edition=fundamental","pubTime":"2026-08-06 19:11","pubTimestamp":1786014685,"startTime":"0","endTime":"0","summary":"Opus Genetics Q2 FY26 net loss widens to $8.1 million; revenue drops to $755,000Opus Genetics posted a net loss of USD 8.1 million, or USD 0.08 per basic share, for the quarter ended June 30, 2026.Revenue fell 73.8% to USD 755,000, on lower license and collaborations revenue tied primarily to its Viatris reimbursement arrangement.R&D expense rose 86.1% to USD 11.21 million, due to higher manufacturing and clinical costs, partly offset by lower phentolamine program costs.Cash and cash equivalents climbed to USD 88.81 million at June 30, with runway into 2029 expected including potential Oberland facility funding.OPGx-BEST1 Cohort 1 topline data is expected in the second week of September; OPGx-LCA5 Phase 3 enrollment completed, dosing planned for Q4.Disclaimer:This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should n","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nNDL7FZnR8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4007","LU2087621335.USD","BK4583","LU1839511570.USD","BK4585","BK4588","VTRS","IRD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657802636","title":"Opus Genetics Inc Q2 Pretax Profit USD -8.098 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2657802636","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657802636?lang=en_us&edition=fundamental","pubTime":"2026-08-06 19:00","pubTimestamp":1786014006,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nPLXTW9DF8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","BK4007","IRD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657768006","title":"Press Release: Opus Genetics Announces Financial Results for Second Quarter 2026 and Provides Corporate Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2657768006","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657768006?lang=en_us&edition=fundamental","pubTime":"2026-08-06 19:00","pubTimestamp":1786014000,"startTime":"0","endTime":"0","summary":"with 3-month topline data from Cohort 1 expected during the second week. of September 2026, assuming all participants complete their assessments. -- Baseline demographics were presented at the Association for Research in. Vision and Ophthalmology  2026 Annual Meeting with the related. poster presentation available on the Publications & Presentations page of. the Opus Genetics website. Additionally, a slide presentation and video. summary recording titled \"OPGx-BEST1 Cohort 1 Baseline Demographics and. Key Endpoints for IRDs\" are provided on the OPGx-BEST1 Program section of. the Opus Genetics website.OPGx-LCA5-- Alignment was achieved with the U.S. Food and Drug Administration . on the registrational Phase 3 clinical trial evaluating OPGx-LCA5 in. eight participants with a six-month run-in period, allowing each. participant to serve as their own control, prior to receiving treatment. -- Enrollment in the trial was completed, with dosing of OPGx-LCA5 expected. to begin in the fourth qua","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4007","IRD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656330819","title":"Wall Street Analysts Are Bullish on Top Healthcare Picks","url":"https://stock-news.laohu8.com/highlight/detail?id=2656330819","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656330819?lang=en_us&edition=fundamental","pubTime":"2026-08-04 00:00","pubTimestamp":1785772852,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Opus Genetics (IRD) and Krystal Biotech (KRYS) with ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/wall-street-analysts-are-bullish-on-top-healthcare-picks-blurbs-news-271?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/wall-street-analysts-are-bullish-on-top-healthcare-picks-blurbs-news-271?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","BK4139","HELX","PSCH","IRD","KRYS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656796513","title":"Opus Genetics Completes Enrollment in Phase 3 Gene Therapy Trial for Rare Blindness Disorder","url":"https://stock-news.laohu8.com/highlight/detail?id=2656796513","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656796513?lang=en_us&edition=fundamental","pubTime":"2026-08-03 20:24","pubTimestamp":1785759877,"startTime":"0","endTime":"0","summary":"Opus Genetics  completed enrollment in its phase 3 registrational trial evaluating OPGx-LCA5, an investigational gene therapy for LCA5-associated inherited retinal disease, a rare condition that can cause blindness, the company said on Monday.The trial was developed in collaboration with the US FDA and could support a future Biologics License Application.Opus expects to begin dosing patients in Q4 and report topline data by the end of 2027. OPGx-LCA5 has received FDA Rare Pediatric Disease, Orphan Drug and RMAT designations, it said.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4007","IRD.AU","BK4139","IRD","BK7129"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656373591","title":"Opus Genetics Completes Patient Enrollment in Registrational Phase 3 Trial of Opgx-Lca5 for Lca5-Associated Inherited Retinal Disease","url":"https://stock-news.laohu8.com/highlight/detail?id=2656373591","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656373591?lang=en_us&edition=fundamental","pubTime":"2026-08-03 19:00","pubTimestamp":1785754800,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260803:nTUABFLGMG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["IRD","BK4007","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656373527","title":"Opus Genetics - May Submit Bla Based on Six-Month Efficacy Data","url":"https://stock-news.laohu8.com/highlight/detail?id=2656373527","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656373527?lang=en_us&edition=fundamental","pubTime":"2026-08-03 19:00","pubTimestamp":1785754800,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260803:nTUABFLGMG:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","BK4007","IRD"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.ocuphire.com;ir.opusgtx.com;www.opusgtx.com","stockEarnings":[{"period":"1week","weight":0.2656},{"period":"1month","weight":0.2354},{"period":"3month","weight":0.1588},{"period":"6month","weight":-0.045},{"period":"1year","weight":2.6484},{"period":"ytd","weight":1.3234}],"compareEarnings":[{"period":"1week","weight":0.0011},{"period":"1month","weight":0.0005},{"period":"3month","weight":0.0443},{"period":"6month","weight":0.1455},{"period":"1year","weight":0.1865},{"period":"ytd","weight":0.1294}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Opus Genetics, Inc., a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of unmet needs of patients with refractive and retinal eye disorders. The company offers Phentolamine Ophthalmic Solution for reversal of mydriasis, as well as is in Phase III clinical trials for presbyopia and dim light or night vision disturbances. Its lead retinal product candidate is APX3330, a small-molecule inhibitor of reduction oxidation effector factor-1 protein that has completed Phase II clinical trial for the treatment of diabetic retinopathy. The company also develops APX2009 and APX2014 that are preclinical product candidates for retina indications. The company was formerly known as Ocuphire Pharma, Inc. Opus Genetics, Inc. was founded in 2018 and is headquartered in Farmington Hills, Michigan.","yearOnYearQuotes":[{"month":1,"riseRate":0.454545,"avgChangeRate":0.077612},{"month":2,"riseRate":0.5,"avgChangeRate":0.090887},{"month":3,"riseRate":0.363636,"avgChangeRate":0.009762},{"month":4,"riseRate":0.428571,"avgChangeRate":0.498458},{"month":5,"riseRate":0.590909,"avgChangeRate":4.154221},{"month":6,"riseRate":0.363636,"avgChangeRate":-0.020512},{"month":7,"riseRate":0.363636,"avgChangeRate":0.000717},{"month":8,"riseRate":0.363636,"avgChangeRate":-0.018884},{"month":9,"riseRate":0.5,"avgChangeRate":0.008305},{"month":10,"riseRate":0.285714,"avgChangeRate":-0.082285},{"month":11,"riseRate":0.285714,"avgChangeRate":-0.065655},{"month":12,"riseRate":0.454545,"avgChangeRate":0.054326}],"exchange":"NASDAQ","name":"OPUS GENETICS INC","nameEN":"OPUS GENETICS INC"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.49.0","shortVersion":"4.49.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"OPUS GENETICS INC(IRD),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest OPUS GENETICS INC(IRD) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"OPUS GENETICS INC,IRD,OPUS GENETICS INC股票,OPUS GENETICS INC股票老虎,OPUS GENETICS INC股票老虎国际,OPUS GENETICS INC行情,OPUS GENETICS INC股票行情,OPUS GENETICS INC股价,OPUS GENETICS INC股市,OPUS GENETICS INC股票价格,OPUS GENETICS INC股票交易,OPUS GENETICS INC股票购买,OPUS GENETICS INC股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"OPUS GENETICS INC(IRD),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest OPUS GENETICS INC(IRD) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction